CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and...

CytomX Therapeutics的股价走高，此前该公司公布了第一季度财务业绩好于预期，并公布了正在进行的 CX-904 1a 期剂量升级临床研究的初步数据，显示出良好的安全性，而且...

Benzinga · 05/08 17:03

CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and Confirmed Anti-cancer Activity.

CytomX Therapeutics的股价走高，此前该公司公布了第一季度财务业绩好于预期，并公布了正在进行的 CX-904 1a期剂量升级临床研究的初步数据，显示出良好的安全状况和证实的抗癌活性。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息